Compositions for improving gut microbiota, behavioral patterns, alpha-synuclein levels, sleep patterns, and / or serum melatonin
Patent Information
- Application Number
- JP2023561727
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-26
- Filing Date
- 2022-04-07
- Publication Date
- 2025-04-14
AI Technical Summary
Children with autism spectrum disorder (ASD) face significant challenges with dysbiosis, behavioral patterns, alpha-synuclein levels, and sleep disturbances, for which there are no definitive treatments, and existing interventions like melatonin supplementation have mixed results.
A composition containing beta-glucan produced by Aureobasidium pullulans AFO-202 is administered to improve intestinal microflora, balancing gut bacteria by reducing harmful species and increasing beneficial ones, thereby addressing ASD, multiple sclerosis, Alzheimer's disease, Parkinson's disease, and epilepsy, and improving sleep patterns and serum melatonin levels.
The composition effectively regulates gut microbiota, leading to improved behavioral patterns, alpha-synuclein levels, and sleep quality in children with ASD, with significant reductions in harmful bacteria and increases in beneficial species, suggesting potential therapeutic benefits for neurological disorders.
Smart Images
Figure 00000000_0000_ABST